Sponsor content
212 result(s) found, displaying 61 to 70
-
Cancellation by sponsorRequested by Takeda Pharmaceuticals Australia Pty Ltd
-
Cancellation by sponsorRequested by Takeda Pharmaceuticals Australia Pty Ltd
-
Prescription medicine decision summaryTGA decision: Exkivity (mobocertinib) is approved to treat lung cancer
-
Prescription medicine registrationActive ingredients: mobocertinib succinate.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TAKHZYRO lanadelumab (rch) 300 mg/2 mL solution for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ENTYVIO vedolizumab 108 mg/0.68 mL solution for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ENTYVIO vedolizumab 108 mg/0.68 mL solution for injection pre-filled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VEYVONDI vonicog alfa 650 IU powder for injection with solvent vials.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VEYVONDI vonicog alfa 1300 IU powder for injection with solvent vials.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Takeda Pharmaceuticals Australia Pty Ltd - Electric infusion pump administration set.